We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Gerresheimer Buys Plastic Vials Maker Centor

By HospiMedica International staff writers
Posted on 23 Aug 2015
Advanced healthcare glass and plastic products manufacturer Gerresheimer (Düsseldorf, Germany) has agreed to purchase plastic vial maker Centor (Perrysburg, OH, USA) for USD 725 million in cash.

Gerresheimer is a leading global partner to the pharmacetical and healthcare industries specializing in glass and plastic products. More...
The comprehensive product portfolio includes safe drug-delivery systems such as insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, as well as cosmetic packaging products. The deal is designed to extend Gerresheimer’s footprint by leveraging Centor’s position as the leading manufacturer of plastic vials and closures for oral drugs in the United States.

Centor, which will be integrated in the plastics and devices division of Gerresheimer, manufactures the Screw-Loc child resistant package, an industry standard for over 40 years, and the 1-Clic vial for dispensed medications, which opens easily with minimal tab pressure and a slight turn, emitting an audible "click" to ensure it is properly secured. The US prescription industry is structured around the “pour-and-count” system, whereby the exact number of prescribed oral drugs is delivered in secure plastic vials.

“Centor is the highly profitable market leader for plastic vials and closures in the prescription retail market,” said Uwe Röhrhoff, CEO of Gerresheimer. “This is a perfect fit to extend our product offering from packaging of parenterals to the packaging of oral drugs in the United States. We expect that this acquisition will increase shareholder value significantly.”

“We are happy to join the Gerresheimer Group with its high expertise in primary pharmaceutical packaging,” said Paul Arsenault, president of Centor. “In the future we will contribute to Gerresheimer’s success with our market leadership in the North American prescription plastic vial retail market.”

Related Links:

Gerresheimer
Centor



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Infant Incubator
OKM 801
Imaging Table
Stille imagiQ2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.